Eusol Biotech Co.,Ltd. (TPEX:6652)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
3.650
-0.640 (-14.92%)
Mar 25, 2026, 1:19 PM CST
Market Cap587.73M -46.3%
Revenue (ttm)370.00K
Net Income-37.78M
EPS-0.28
Shares Out137.00M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,000
Average Volume139,705
Open4.200
Previous Close4.290
Day's Range3.510 - 4.300
52-Week Range3.610 - 10.200
Beta-0.85
RSI24.67
Earnings DateMar 31, 2026

About Eusol Biotech

Eusol Biotech Co.,Ltd. focuses on research and development of new drugs for the treatment of nerve injuries. The company’s pipeline includes ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) for spinal cord injury, and SM-1, a 3-in-1 combination sleeping aid. It also offers small molecule drugs including EPS221, a selective serotonin reuptake inhibitor; EPS222, a calcium channel blocker for cardiovascular disease; EPS251, a drug for rheumatology/anti-inflammation; and EA2501, a drug for anticoagulation. The company was founded... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1994
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6652
Full Company Profile

Financial Performance

Financial Statements